Until recently the use of proteomics in the biomedical arena has included programmes aimed at the elucidation of cellular responses to extracellular stimuli by known and potential drugs. It has been anticipated that these will lead to the elucidation of the basic mechanisms of cellular responses, potential identification of new drug targets and discovery of the mechanism of action of drugs both NCE’s and those currently in development.
Until recently the use of proteomics in the biomedical arena has included programmes aimed at the elucidation of cellular responses to extracellular stimuli by known and potential drugs. It has been anticipated that these will lead to the elucidation of the basic mechanisms of cellular responses, potential identification of new drug targets and discovery of the mechanism of action of drugs both NCE’s and those currently in development.
Until recently the use of proteomics in the biomedical arena has included programmes aimed at the elucidation of cellular responses to extracellular stimuli by known and potential drugs. It has been anticipated that these will lead to the elucidation of the basic mechanisms of cellular responses, potential identification of new drug targets and discovery of the mechanism of action of drugs both NCE’s and those currently in development.
In addition, the use of proteomics to investigate toxic responses to drugs (toxicoproteomics) in pre-clinical and clinical studies has gained increasing importance, particularly when such data is analysed in the context of more traditional toxic responses. Notably, many of these studies are now undertaken in the context of multi-team groups or a consortia of researchers from different disciplines – including proteomics. An interesting example of such a consortium is the EU and commercially funded ‘PredTox’ predictive toxicology programme being undertaken by a range of companies and Universities; the programme forms part of the ‘Innovative Medicines for Europe’ initiative. There are important lessons to be learnt from the operational management of such consortia (to be discussed further on within the article). The PredTox programme is exemplary of the growing interest in the use of ‘omics technologies, including proteomics, to identify ‘biomarkers’, as well as a vibrant debate on the relative importance of biomarkers for revenue generation in the pharma sector. Here, the term ‘biomarkers’ will be defined in the context of proteomics, an historical overview of the evolution of proteomics technologies and their continuing development will be given, and some recent biomarker discovery projects will be outlined with the use of selected examples. To conclude, some of the lessons learnt and challenges that remain in biomarker discovery, validation and implementation will be summarised.
What is a biomarker?
It is interesting to try to establish ‘de novo’ the definition of a biomarker and the aims of current activity in this arena. Even a cursory ‘dip’ into web search engines produces hundreds of thousands of results for the term biomarker, and many of these give ‘definitions’. For example, the Oxford English Dictionary defines a biomarker as; “A substance used as an indicator of the presence of material of biological origin, of a specific organism, or a physiological condition or process; spec. a diagnostic indicator of (predisposition to) a medical condition.” “Substance”, “indicator” and “medical condition” could be considered as the most important words within this definition and it these connotations that formed the succinct (and elegant) definition used by Sir Richard Doll who suggested that a biomarker is the “Linkage between ‘measurable’ event(s) and disease”. Sir Richard published a landmark paper in 1954 showing the association between smoking and lung cancer. He then continued follow up studies for a further 50 years [see ‘The mortality of doctors in relation to their smoking habits: a preliminary report’, which was reprinted from Br Med J 1954:ii;1451-5 in 20041]. It is notable that biomarker(s) can and should be regarded as more than just a single measurable event and so might represent a combination of parameters; in the present context it is important to emphasise that the events may not all be changes in protein expression. The search for a single protein biomarker of required sensitivity and specificity for clinical use is now almost certainly an unrealistic objective and, as noted later; methods to integrate data from measurement of ‘events’ continue to require considerable refinement and improvement. In particular, there is a growing appreciation that imaging data and molecular data (perhaps including mass spectrometry based molecular imaging) could be integrated to great effect. There are a number of arenas including analysis of individual disease areas in which biomarker discovery makes an impact, these include: protein expression signatures as biomarkers, biomarkers for drug safety assessment, biomarkers for NCE characterization, biomarker assay development and validation and, of course, the use of biomarkers in go versus no-go decisions in drug development. It should be noted that the diversity of current proteomics methods for the discovery of biomarkers is not at present matched by the availability of protein assays that are used in clinical practise. The gold standard assay is the ELISA, however, the length of time in which this will remain the case is a subject of interesting debate. Other platforms include multiplexed immuno-assays on solid surfaces (including microarrays) and bead based assays. More exciting developments in mass spectrometry based imaging and quantitative assays of peptide/protein expression are underway, although in reality they are a long way from gaining widespread acceptance/use in research and (more importantly) clinical applications.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
The evolution of proteomics for biomarker discovery
The term “proteome” was first coined in 1995 by Marc Wilkins and his colleagues2 and was defined as the “protein complement of a genome”. However, the term “proteomics” has now come to be regarded as the global analysis of the proteins expressed in normal biological processes (e.g. development, cell cycle, ageing, apoptosis), in response to the environment (drugs, toxic agents) and in disease states. In its use to measure the expression (including localisation, turnover and modification) of proteins it is regarded as providing the opportunity for protein-based “discovery”. The results of proteomics studies can provide important new insights into the molecular basis of biological processes in both health and disease, identifying new biomarkers that can be exploited as diagnostic/prognostic reagents and/or as therapeutic targets. In general proteomics biomarker discovery experiments follow a relatively straightforward workflow of:
Sample acquisition and preparation. The importance of this initial step in the discovery process cannot be over-emphasized. There are many pre-existing biobanks (collated collections of samples) but in reality the samples contained within them were often obtained from different poorly co-ordinated studies, using different protocols (not following standard operating procedures), and are not age-matched or otherwise suitably matched for the objectives of the investigation. Samples can include biological fluids, tissues – including biopsies (disease vs. normal), cells and sub-cellular components (membranes / mitochondria/ nuclei etc.);
Protein/peptide separation. This is achieved by a now bewildering array and combination of approaches including one and two-dimensional gel electrophoresis and liquid chromatography based separations;
Protein/peptide detection and protein/peptide identification/quantification. The techniques used include covalent modification of proteins with fluorophores prior to separation (DIGE), conventional dye detection of proteins with mass spectrometry (MALDI and ES) for identification and quantification. These MS techniques convert biomolecules which are polar and charged into gas-phase ion, before subsequently being analyzed. There are many diverse MS analysers available in the proteomic research field including: time of flight (TOF), quadrupole, ion trap, and the fourier transform-ion cyclotron resonance (FT-ICR).
Despite numerous advances in b) and c) the separation of intact proteins by high-resolution two-dimensional gel electrophoresis (2-DE) remains one of the most popular of the “discovery” proteomics workflows3. Following separation and sensitive detection of the separated proteins; often using fluorescence based methods, the 2-D protein spot patterns are subjected to differential semi-quantitative analysis using one of a range of commercially available computer packages. In brief, this process typically involves: image digitization, image filtering, background subtraction, spot detection (e.g. by Gaussian fitting, Laplacian and second derivatives, edge detection), landmarking, matching, and analysis (quantitative, qualitative, statistical). This process continues to be a major bottleneck in the analysis of proteomic data from 2-D gels as intrinsic variability in the shape and distibution of the protein ‘features’ necessitates extensive manual interaction with the software, rendering it at best a semi-automated process4. The combination of fluorescent dye labeling (DIGE) with the ‘Progenesis’ software package (Non-Linear Dynamics) is obtaining increasing acceptance and adoption as a currently effective platform.
In alternative proteomics workflows, samples are initially digested to peptides (usually with trypsin) and the peptides then analysed by tandem mass spectrometry (MS/MS), normally coupled either on or off-line to one or liquid chromatography steps. This approach, often termed “shotgun” proteomics or, a version of it; MudPIT5, is very powerful in identifying large numbers of proteins in a complex mixture. However, this approach is inherently non-quantitative and not currently amenable to large numbers of samples that might be required for a statistically valid method for biomarker discovery. To overcome the problem of quantitaties, peptide based approaches can be combined with stable isotope labeling strategies, such as SILAC, ICAT, or iTRAQ6 In this combined workflow, one of each pair of samples is labeled, either at the level of whole cells (e.g. SILAC), intact proteins (e.g. ICAT) or tryptic peptides (e.g. iTRAQ), with a stable isotope labeled form of the particular reagent. The two (or four in the case of iTRAQ) samples are then combined (multiplexed) and processed further together. The resulting peptides coded in this way then appear during MS as clusters of ions separated by the mass difference in the coding agents or by the release of the mass tag (iTRAQ). The ratio of the ion intensities of these clusters or the mass tag is then a measure of the relative abundance in the samples of the protein from which the particular peptides was generated. The analysis of the complex spectra to generate this relative quantitative information is challenging and there is considerable scope for the development of new and improved approaches. More recently there has been growing interest in the use of ‘signature’ peptides for quantitative and sensitive measurement of protein expression7, 8, 9.
Thus, as in transcriptomics there are a bewildering array of potential platforms, and choosing the most appropriate for the task in hand can be difficult. It is often a decision that has to combine a range of factors which vary during the implementation of the discovery process. As a general observation, it seems unfortunate that there appears to be such intense competition to promote an exclusive paramount technology (which necessarily emphasises the shortcomings of the alternatives); with the consequence that opportunities for mutually compatible and even synergistic combinations platforms of over-lapping capabilities may be being unnecessarily overlooked.
Application of proteomics for biomarker discovery
In our own research portfolio we have and continue to undertake biomarker discovery in diverse areas including pancreatic cancer, prostate cancer and predictive toxicology; including the development of a quantitative ‘assay’ for the simultaneous measurement of the expression of cytochrome P450 isoforms. In pancreatic cancer we have effectively applied careful sample acquisition and preparation (using laser capture microdissection) with 2-DE and MS to identify potential biomarkers of the disease. One such biomarker, S100A6 protein, has been ‘validated’ by immuno histochemistry of tissue microarrays and ‘linkage’ between the expression of high levels of S100A6 in the nuclei of ductal cells of the pancreas as a prognostic indicator of disease outcome10, 11. In prostate cancer, as part of an Irish Cancer Fund supported consortium of hospitals and research institutes, proteins and metabolites in semen and urine12, 13 are being sought to identify more effective biomarkers than the prostate specific antigen (PSA) which are currently used. PSA is one example of the many current diagnostic markers that have acknowledged no effective replacement (supplement). Alongside these studies we (in common with many others) are undertaking proteomic biomarker analysis of patient response to treatment, in our case detailing the response to combined chemo and radiotherapy treatment of prostate cancer. This has highlighted the need to implement a robust process for sample accrual (during patient follow-up) and the necessary long-term nature of such studies. For us, these studies have highlighted some of the conclusions that may be drawn from current approaches and some of the questions that remain for biomarker discovery (Figure 1).
Teamwork, high quality samples, flexible application of discovery technologies and the ability to integrate data have proven to be extremely important. Remaining questions include the identification of current bottlenecks in the technologies and their exploitation, as well as ways in which the data generated can be implemented into a clinically relevant process of disease/patient assessment and monitoring (Figure 1). The latter represents a major undertaking that may need to be co-ordinated with other innovative approaches for patient assessment and monitoring to assist clinical decision making. It has been noted that the increasingly large and detailed array of information must be presented in a form that can be processed by the human user14; this in itself will be a major undertaking.
Conclusion
What is likely to make the application of proteomics to biomarker discovery successful? The building of effective teams is one of the most challenging aspects; industry has a theoretical head start in that it is assumed that everyone working for the company has the companies’ success as a shared goal, whilst in academia there may be a greater element of self-directed motivation. In any environment flexibility, motivation and generosity in the sharing of success is essential. It is also reasonably obvious that an ideal discovery scenario would be one that has unlimited resources: from sample availability, to instrumentation and software as well as a flexible ability to ‘follow through’ on discoveries in an appropriate manner. There are so many potential avenues of opportunity afforded by proteomics based discoveries that future ‘follow through’ could require the implementation of new experimental approaches not already in the research teams ‘armoury’. An all embracing, watchful and objectively critical appraisal of new and unfamiliar technologies is likely to be essential for competitive success in the demanding but potentially profitable arena of biomarkers.
Figure 1: Observations from proteomic biomarker discovery programmes. Key conclusions and remaining questions. Notably, the precise definition of the research and clinical question or hypothesis under investigation needs to be cleary articulated and shared by the team of researchers, nurses, clinicians and informaticians involved.
References
Doll, RA and Hill, AB. (2004) British Medical Journal, 328, 1529-1533.
Wasinger, VC, Cordwell, SJ, Cerpa-Poljak, A, Yan, X, Gooley, AA, Wilkins, MR, Duncan, MW, Harris, R, Williams, KL, and Humphery-Smith, I. (1995). Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis, 16, 1090-1094.
Gorg A, Weiss W, Dunn MJ. (2004) Current two-dimensional electrophoresis technology for proteomics. Proteomics 4, 3665-3685.
Dowsey AW, Dunn MJ, Yang GZ. (2003) The role of bioinformatics in two-dimensional gel electrophoresis. Proteomics 3, 1567-1596.
Wolters DA, Washburn MP, Yates JR 3rd. (2001) An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem. 73, 5683-5690.
Julka S, Regnier F. (2004) Quantification in proteomics through stable isotope coding: a review. J Proteome Res. 3, 350-363.
Jenkins RE, Kitteringham NR, Hunter CL, Webb S, Hunt TJ, Elsby R, Watson RB, Williams D, Pennington SR, Park BK. (2006) Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags. Proteomics 6,1934-1947.
Aebersold, R. (2007) Quantitative proteomics and systems biology FASEB J., 21, A212
Barnidge, DR, Goodmanson, MK, Klee, GG and Muddiman, DC (2004) Absolute Quantification of the Model Biomarker Prostate-Specific Antigen in Serum by LC MS/MS Using Protein Cleavage and Isotope Dilution Mass Spectrometry J. Proteome Res., 3, 644-652.
Shekouh AR, Thompson CC, Prime W, Campbell F, Hamlett J, Herrington CS, Lemoine NR, Crnogorac-Jurcevic T, Buechler MW, Friess H, Neoptolemos JP, Pennington SR, Costello E. (2003) Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 3, 1988-2001.
Vimalachandran D, Greenhalf W, Thompson C, et al. (2005) High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 65:3218-3125.
Downes, MR, Byrne, JC, Dunn, MJ, Fitzpatrick, JM, Watson, RWG and Pennington SR (2006) Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: A review. Biomarkers, 11, 406 – 416.
Tyers, M. and Mann, M. (2003) Nature 422, 193-197.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.